Drug intelligence / Profile preview

diacetyldianhydrogalactitol

Development stage
Unknown
Lead developer
Kintara Therapeutics
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Diacetyldianhydrogalactitol** is an acetylated derivative of dianhydrogalactitol (DAG), sometimes referred to as dianhydro-3,4-diacetylgalactitol or 3,4-di-O-acetyl-1,2:5,6-dianhydrogalactitol[2][4]. The compound is a small molecule with a chemical formula C10H14O6 and a molecular weight of 230.22 g/mol[2]. It is structurally related to dianhydrogalactitol, a DNA-alkylating agent with antineoplastic activity. Diacetyldianhydrogalactitol and related analogs may act as bifunctional alkylators, forming DNA cross-links via the diepoxide motif after metabolic activation, leading to disruption of DNA function and cell cycle arrest[4]. Diacetyldianhydrogalactitol is considered a chemical derivative/prodrug of dianhydrogalactitol and may possess similar cytotoxic and antitumor properties, although specific pharmacology and clinical testing status for diacetyldianhydrogalactitol are less well characterized in the literature.

Other names
dianhydro-3,4-diacetylgalactitol3,4-di-O-acetyl-1,2:5,6-dianhydrogalactitolGalactitol 1,2:5,6-dianhydro- 3,4-diacetate
02

Targets

N7-G (DNA guanine-N7 adduct)

Beyond the preview

Go deeper on diacetyldianhydrogalactitol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diacetyldianhydrogalactitol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call